anavex.com/post/anavex-s-bl...
They are also getting close on Parkinson’s Dementia so all my fingers and toes are crossed on blarcamesine.
“ in the Phase IIb/III study analysis: Over 48 weeks, blarcamesine significantly slowed clinical progression by 36.3% in the primary endpoint ADAS-Cog13 [LS mean ADAS-Cog13 difference of -2.027; P=0.008] in the ITT analysis. This signal was even stronger in the pre-specified common SIGMAR1 wild type (WT) group with slowed clinical progression by 49.8% at 48 weeks in the active group vs. placebo, respectively [LS mean ADAS-Cog13 difference of -2.317; P=0.015]. Equal analysis with CDR-SB led to comparable consistent results.”
UPDATE on phase 3 clinical trial progress from Zhittya Genesis Medicine
How many know that H2, hydrogen water has positive effects for those with Parkinsons? I didn't know.
Inosine
Isn't this the most dramatic trial so far?
